Ethnic Differences on Long Term Outcomes of Polypoidal Choroidal Vasculopathy after Predominantly Bevacizumab Monotherapy.

Aaron Yap (aaron.yap8@gmail.com)  
The University of Auckland  
Nancy Wang  
The University of Auckland  
David Squirrell  
The University of Auckland

Research Article

Keywords: Polypoidal choroidal vasculopathy, Bevacizumab, Treatment Outcomes, Real-World Study, Long Term

Posted Date: February 9th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1317439/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: A 3-year single-centre, retrospective, comparative, non-randomized cohort study to describe the long-term outcomes of treatment-naïve, Caucasian and non-Caucasian eyes with polypoidal choroidal vasculopathy (PCV) after treatment with predominantly Bevacizumab monotherapy or in combination with rescue photodynamic therapy (PDT).

Methods: Demographics, visual outcomes, optical coherence tomography (OCT) and treatment data were collected up to 3 years after the first visit. Stratified analysis according to ethnicity and baseline vision was performed to identify factors predictive of long-term visual improvement and maintenance.

Results: A total of 89 eyes with PCV were identified, of which 14 received rescue verteporfin PDT. There was an equal distribution between Caucasian and non-Caucasian individuals. Non-Caucasians present at a younger age (75.4 vs 68.9 years, p=0.002), have a higher proportion of foveal involvement (52.1% vs 82.9%, p=0.003) and lower baseline visual acuity (62.9 vs. 52.7 letters, p=0.02). Mean visual acuity (VA) gain was + 8.8 letters and +5.0 letters at one and three years of follow up, respectively. Non-Caucasian individuals had a lower mean final VA compared to Caucasian individuals (54.7 vs. 70.5, respectively; P <0.001). The mean total number of injections given over three years was 14.

Conclusions: Most patients treated with predominantly Bevacizumab anti-VEGF monotherapy achieved sustained visual acuity gains out to 3 years. Due to ethnic-specific differences in PCV phenotypes, non-Caucasians presented with lower baseline VA and had poorer long-term visual outcomes and may have benefited from early PDT or switch to alternative anti-VEGF agents.

Background

Since its first description in the 1990s, the literature on Polypoidal Choroidal Vasculopathy (PCV) has expanded rapidly. Attempts to categorise PCV according to features observed on multimodal imaging across different contexts have yielded classifications that are increasingly complex and not readily translated to clinical practice. As a result, PCV is best considered as a wide spectrum of disease, within which there are a number of well recognised and characteristic diagnostic criteria. Whilst the pivotal trials, EVEREST and PLANET, have provided important guidance with respect to the management of PCV, they were predominantly conducted in large Asian centres, raising the possibility that the results may have limited generalisability to mixed populations with wider phenotypic variations of PCV.

It has recently been recognised that there may be distinct differences between the phenotypes of PCV seen in Caucasian and non-Caucasian eyes. However, little is known about whether this translates into differences in long term visual outcomes and response to available treatments. Auckland, with its diverse ethnic population, facilitates comparison of treatment outcomes across patients from different ethnic groups treated at a single tertiary centre. The aim of this study was to evaluate the three-year visual outcomes of patients with PCV treated with predominantly Bevacizumab monotherapy and to identify if ethnic-specific differences in PCV phenotypes influenced long-term visual outcome.

Methods

We performed an observational cohort study of the outcomes of eyes diagnosed with PCV, within the Auckland District Health Board, New Zealand (NZ) Fight Retinal Blindness (FRB!) database. The patient selection process is detailed in figure 1. As not all clinicians utilise FRB!, the indocyanine green angiography (ICG) diagnostic logs of the eye department were also reviewed to ensure that all patients diagnosed in the unit with PCV between 2005-2017 were included. All patients had to be treatment naïve and meet either the current standard ICG or OCT diagnostic criteria for PCV. Only eyes with complete three year follow up data were included in the final analysis. Reasons for non-completion and baseline demographics of non-completers were recorded. The cohort was divided into two groups, Caucasian and non-Caucasian, to investigate the influence that ethnicity may play in both the presentation and response to treatment.

Briefly, the FRB! database is a cloud-based, record-keeping software that stores data from each clinical visit. Entry datapoints include best-corrected VA, lesion subtype (classic, occult, PCV), greatest linear diameter (baseline), lesion activity, treatment, and
any ocular adverse events. VA is recorded in equivalent logarithm of the minimum angle of resolution (logMar) letters. Treating physicians determined all management decisions, including frequency of visits and treatment method, thereby reflecting real-world practice. Lesion activity status was graded by the treating physician based on optical coherence tomography (OCT), ICG, or a combination of both, at each visit. Baseline ICG and OCT of all patients so identified were reviewed to determine baseline lesion characteristics. In cases of missed or incomplete entries, data was corroborated by a retrospective review of physical records.

Outcome Measurements

The primary study outcome was the mean VA over three years after initiating treatment. Secondary outcomes were the proportion of eyes that achieved lesion inactivity, time to inactivity, median number of injections per year, and proportion receiving photodynamic therapy (PDT), Aflibercept or Ranibizumab. Self-reported ethnicity data was extracted from the clinical records. Individuals who identified with more than one ethnicity were routinely classified to a single ethnicity based on a defined prioritized order. Stratified analysis according to Caucasian and non-Caucasian ethnicity, and baseline vision were performed. Patients that were discharged following poor visual prognosis had their last visual acuity measured brought forward for final analysis.

Statistical Analysis

Descriptive data are presented as mean (standard deviation), mean (95% confidence interval), or number (percentage). The Student T-test, Fisher's test, Wilcoxon test was used to compare the differences in baseline characteristics and final visual outcomes between different groups. P-value of less than < 0.05 was considered statistically significant. All statistical analysis was performed using IBM SPSS® Statistics (Release 27.0.1.0).

Kaplan Meier survival curves were used to display the time to inactivity. Locally Weighted Scatterplot Smoothing curves (LOESS) were used to plot the visual acuity trends for different ethnic groups and eyes with varying baseline vision. All graphs were produced using GraphPad Prism© Version 9.2.0 (283).

Results

Study participants

Table 1: Baseline characteristics
Caucasian | Non-Caucasian | p-value | Total cohort
--- | --- | --- | ---
No. of eyes (%) | 48 (53.9%) | 41 (46.1%) | - | 89
No. bilateral (%) | 7 (17.1%) | 4 (10.8%) | 0.524* | 11 (%)
Mean age (SD), yrs | 75.4 (9.8) | 68.9 (8.0) | 0.002** | 72.3 (9.5)
Gender, male (%) | 14 (34.1%) | 19 (51.4%) | 0.169* | 33 (42.3%)
Mean baseline VA (SD), letters | 62.9 (16.3) | 52.7 (22.3) | 0.02*** | 58.2 (19.9)
VA ≥70 letters (20/40 Snellen) | 18 (37.5%) | 9 (22.0%) | 0.165* | 27 (30.3%)
VA ≤ 35 letters (20/200 Snellen equivalent) | 4 (8.3%) | 8 (19.5%) | 0.212* | 12 (13.5%)
Presence of BVN, no (%) | 20 (41.7%) | 27 (65.9%) | 0.033* | 47 (52.8%)
Foveal involvement, no. (%) | 25 (52.1%) | 34 (82.9%) | 0.003* | 59 (66.3%)
Cluster/String Configuration, no. (%) | 24 (50%) | 29 (70.7%) | 0.054* | 53 (59.6%)
Solitary polyp Configuration, no. (%) | 13 (27.1%) | 5 (12.2%) | 0.113* | 18 (20.2%)
Early filling†, no. (%) | 8 (16.7%) | 16 (39.0%) | 0.03* | 24 (27.0%)
Late filling‡, no. (%) | 24 (50%) | 15 (36.6%) | 0.284* | 39 (43.8%)
Mean (SD) Central Retinal Thickness, microns | 385 ± 160 | 387 ± 197 | 0.659*** | 386 ± 176
Mean GLD (SD), microns | 2657 (1383) | 4216 (1954) | 0.008*** | 3552 (1885)

SD: Standard deviation; GLD: greatest linear diameter; IQR: interquartile range; VA: visual acuity; BVN: Branching vascular network

† Polyp fill during arteriolar phase of ICG
‡ Polyp fill during late venous phase of ICG
* Fisher exact test.
** Student t-test
*** Wilcoxon rank-sum test.

From the Auckland DHB FRB! database and ICG diagnostic logs, a total of 89 eyes met all the eligibility criteria specified in Figure 1. Baseline characteristics of the study cohort are outlined in Table 1. Fifty-three percent of patients were NZ European, 27% Asian, 13% Pacific Islander and 5% were NZ Māori. To examine for differences in ethnicity, patients were subcategorised into Caucasian (53%) and non-Caucasian eyes (47%). The mean baseline VA was higher in Caucasian participants compared with non-Caucasian participants (62.9 ± [SD 16.3 letters] vs. 52.7 ± [SD 22.3 letters], respectively; P = 0.02). Non-Caucasian individuals were more likely to present at a younger age with larger lesions which were associated with branching vascular networks. Their lesions also had a predilection to involve the fovea. Baseline ICG, where available, revealed that non-Caucasian individuals were also more likely to have string or cluster of polyps, which filled early in the ICG transit.

Non-completion rate

Table 2: Demographics of patients that were lost to follow up and excluded due to incomplete data.
### Ethnicity no. (%)

| Ethnicity       | No. | (%) |
|-----------------|-----|-----|
| Caucasian       | 12  | 71% |
| Non-Caucasian   | 5   | 29% |

### Gender no. (%)

| Gender | No. | (%) |
|--------|-----|-----|
| Male   | 6   | 35% |
| Female | 11  | 65% |

| Mean age (SD), years | 73.1 (12.5) |
|----------------------|-------------|
| Mean baseline VA (SD), letters | 61.5 (13.3) |
| Mean final VA at last visit (SD), letters | 71.4 (9.4) |
| Mean Follow Up Time (SD), months | 20.5 (5.7) |

SD: Standard deviation; VA: Visual acuity

Seventeen patients were excluded. The reasons included: Patient death, the patient elected to seek care outside of the public hospital, the patient was referred from to Auckland from another unit solely for an ICG, the patient left Auckland during treatment and either moved to a different hospital catchment or left the country (Figure 1). The demographics of this population is outlined in table 2. This represents 17% of all eyes that were commenced on treatment for PCV in our unit. The mean duration of follow up of the non-completers was 20.5 months and the final mean VA was 71.4 letters. Of those that were discharged, three patients had their last measured VA brought forward after discharge with futile visual prognosis (VA ≤ 35 letters). The remaining four patients were discharged after a long period of inactivity. These patients, along with those deceased, all had a last measured VA of greater than 60 letters. Given the unpredictability of their future visual outcome, their last measured VA was not carried forward for final analysis. The baseline demographics of those eyes that were excluded were broadly comparable to the study cohort [Table 2 vs Table 1], including mean baseline vision (61.5 ± SD 13.3 vs. 58.2 ± SD 19.9, p=0.641).

### Visual outcomes

The mean visual acuity for all eyes for each year is displayed in Table 1 and Figure 2A. Overall, there was a 8.9 letter gain from baseline at 12 months. At three years, there was a mean gain of 5.0 letters compared to baseline (63.2 ± [SD 21.0] letters vs 58.2 ± [SD 19.9 letters], respectively, p=0.021). All other visual outcomes are outlined in table 2. The only significant difference between ethnicities was that non-Caucasian individuals (54.7 ± SD 25.8 letters) had a lower mean final VA compared to Caucasian individuals (70.5 ± [SD 25.0 letters], P <0.001). Figure 2B plots the mean visual change over three years for Caucasian and non-Caucasian individuals. The largest gains in vision occurred within the first year for both Caucasian and non-Caucasian individuals, with both groups achieving a mean improvement in visual acuity gain of 8.8 letters.

The mean visual change over three years, stratified according to baseline visual acuity, is shown in figure 2C. Eyes were stratified into 3 groups according to their presenting baseline VA: (1) good baseline vision of 70 letters or more (27 eyes), (2) moderate baseline vision of between 36 and 69 letters (50 eyes), and (3) low baseline vision of 35 letters or fewer (12 eyes). The mean VA of eyes with good baseline vision was initially 74.3 letters (SD 7.2), dropping down to 70.2 (SD 18.5) letters at year three; an increase of 7.6 letters. Eyes with poor baseline vision had a mean baseline VA of 22.4 letters (~20/400) and experienced an increase of 23.1 letters (~20/160) at 3 years; all improvement occurred in the first year of treatment. Overall, those who presented with good vision had a better final VA at 3 years compared to those who started off with poor vision. (70.2 ± [SD 17.4] vs. 45.5 ± [SD 28.8], p= 0.007).

Table 3: Comparison of visual outcomes between different ethnic groups.
|                         | 12 months | 36 months | 36 months (Caucasian) | 36 months (Non-Caucasian) | p-value |
|-------------------------|-----------|-----------|-----------------------|---------------------------|---------|
| No. of eyes             | 89        | 89        | 48                    | 41                        | -       |
| Mean ± SD final VA, letters | 67.0 ± 16.4 | 63.2 ± 21.0 | 70.5 ± 12.0            | 54.7 ± 25.8               | <0.001* |
| Mean ± SD CRT, microns  | 307.3 ± 146.5 | 295.4 ± 122.2 | 269.9 ± 77.0            | 327.0 ± 157.2              | 0.269*  |
| Mean change in VA letters (95% CI) | +8.9 (2.7 to 10.5) | +5.0 (-2.7 to 8.8) | +7.6 (3.2 to 12.0) | +2.0 (-5.8 to 9.8) | 0.581*  |
| Proportion with ≥15-letter gain | 24 (27.0%) | 29 (32.6%) | 17 (35.4%) | 12 (29.3%) | 0.651** |
| Proportion with ≤15-letter loss | 84 (94.4%) | 78 (87.6%) | 44 (91.7%) | 34 (82.9%) | 0.333** |
| VA ≥ 70 letters (20/40 Snellen equivalent) | 48 (53.9%) | 47 (52.8%) | 33 (68.8%) | 14 (34.1%) | 0.001** |
| Mean total ± SD, no. of injections | 5.8 ± 2.9 | 13.8 ± 8.1 | 14.0 ± 8.1 | 13.6 ± 8.1 | 0.833*** |
| Received PDT, no. (%) | 5 (5.6%)  | 14 (15.7%) | 4 (8.3%)  | 10 (24.4%) | 0.08**  |
| Mean time to PDT (SD), months | -        | -         | 30 (15.2) | 19.1 (15.6) | 0.185*** |
| Received Afibercept or Ranibizumab, no. (%) | 6 (6.7%) | 15 (16.9%) | 11 (22.9%) | 4 (9.8%) | 0.155** |

CRT: Central Retinal Thickness; VA: visual acuity; CI: confidence interval; SD: Standard deviation; PDT: photodynamic therapy

* Wilcoxon Rank-Sum test.
** Fisher’s exact test.
*** Student t-test

Secondary outcomes

Kaplan-Meier survival curve representing the proportion of eyes achieving inactivity is shown in Figure 3. Seventy-four percent of patients achieved lesion inactivity by 12 months, rising to 88% at 24 months. Overall, the mean central retinal thickness dropped by 82 microns within the first year (386 ± [SD 176 microns] vs 307 ± [SD 147 microns], paired T-test p<0.001) and remained stable until year three (295 ± [SD 122 microns]). [Table 3]

The median number of injections delivered in the first year was 6 and ranged between 3 to 4 injections during maintenance years. The total mean number of injections given to study completers at the end of 3-years was 13.8. There was a higher mean total number of injections given to those that had a final vision of greater than 70 letters at three years, compared to those with vision worse than 35 letters (13.2 ± 7.9 vs 9.6 ± 5.9, p=0.182, respectively). The majority of Caucasian eyes received Bevacizumab anti-VEGF monotherapy, with just 8% of eyes receiving PDT. A higher proportion of non-Caucasian eyes received PDT (24%), but this trend did not achieve statistical significance. The mean time to application of PDT (30 months for Caucasians vs 19 months for Non-Caucasians) indicates it was being used for late, rescue treatment in both cohorts.

Discussion

This study evaluates the real-world outcomes of patients with PCV in a single tertiary unit that serves an ethnically diverse population. Overall, there was a sustained visual benefit up to three years. Most patients were treated with Bevacizumab anti-VEGF monotherapy, with a proportion of both cohorts receiving late, rescue PDT. There was an initial mean VA gain of 8.8 and
5.0 letters at years one and three respectively. Stratified analysis according to baseline visual acuity, revealed that a poor VA at presentation was predictive of a poor visual outcome at 3 years, despite significant improvements being achieved in the first year of treatment.

Table 4 compares the clinical outcomes observed in the current study with previously published real-world observational studies for PCV. Whilst the data is very heterogenous, three key themes emerge; 1. All long-term studies demonstrate peak visual gains at 1 year, with a subsequent decline in the following maintenance years, regardless of therapeutic regimen.\textsuperscript{10-14} 2. There is a paucity of long-term data from Caucasian populations with PCV and thus there are few comparisons of visual outcomes based on ethnicity. 3. Consistent with the EVEREST trials, combination therapy, at least in non-Caucasians is associated with superior visual outcomes, despite fewer injections.\textsuperscript{14-17}

Table 4. Comparison of Clinical Outcomes in the Current Study with Previously Published Real-World Observational Studies for Polypoidal Choroidal Vasculopathy Composing Different Ethnic Compositions Treated with Anti-Vascular Endothelial Growth Factor Monotherapy or Combination Therapy with Verteporfin Photodynamic Therapy.
| Author, number of eyes | Ethnicity of Population | Baseline VA, logMar letters | VA 1 year, logMar letters | VA 3 years, logMar letters | Mean total number of injections, follow up duration, anti-VEGF agent | Photodynamic therapy |
|------------------------|-------------------------|-----------------------------|--------------------------|--------------------------|---------------------------------------------------------------|---------------------|
| Teo, 193<sup>25</sup>   | Caucasian 65            | 46<sup>+</sup> - 60<sup>‡</sup> | 67.5<sup>†</sup> - 70<sup>‡</sup> | -                        | 4.3<sup>‡</sup> – 6.4<sup>‡</sup> over 12 months Predominantly bevacuzimab | Mean of 1.23 treatments within initial 3 months |
|                        | Non-Caucasian 115       |                            |                          |                          |                                                               |                     |
|                        | Undisclosed 13           |                            |                          |                          |                                                               |                     |
| Current cohort, 48      | Caucasian               | 62.9                        | 71.7                     | 70.5                     | 14 over 3 years                                               | 4 had PDT, none in the first year |
| Chehab, 50<sup>26</sup> | Caucasian               | 59.9<sup>†</sup>            | 60.4<sup>‡</sup>         | -                        | 8.4-8.6 over 24 months Ranibuzimab/Aibercept                | 15 had PDT, with 6 in the first 6 months. |
| Gharehbagh, 29<sup>12</sup> | Caucasian              | 62<sup>‡</sup>            | 66<sup>§</sup>          | -                        | 7.6 over 22 months Aibercept                                 | 7 had PDT |
| Current cohort, 41      | Non-caucasian           | 52.7                        | 61.5                     | 54.7                     | 13.6 over 3 years                                             | 10 had PDT, 5 in the first year |
| Fenner, 199<sup>16</sup> | Non-caucasian           | 41.6<sup>†</sup> – 45.1<sup>‡</sup> | 48.2<sup>†</sup> – 55.9<sup>‡</sup> | -                        | 5.0<sup>†</sup> - 5.6<sup>‡</sup> over 12 months Predominantly bevacuzimab | 100 had PDT, 66 in the first 3 months |
| Miyata, 61<sup>27</sup>  | Non-caucasian           | ~65 (0.4<sup>†</sup> - 0.41<sup>‡</sup>) | ~70-73 (0.26<sup>†</sup> - 0.29<sup>‡</sup>) | ~68 (0.32<sup>†</sup> - 0.33<sup>‡</sup>) | 5.3<sup>†</sup> – 9.2<sup>‡</sup> over 5 years Ranibuzimab    | 20 had initial PDT |
| Wataru, 53<sup>15</sup>  | Non-caucasian           | ~57 (0.55)                   | ~70<sup>§</sup>          | ~70<sup>§</sup>           | 7.51 over 5 years Ranibuzimab/Aibercept                       | All had initial PDT |
| Chang, 31<sup>11</sup>  | Non-caucasian           | ~60 (0.52)                   | ~63 (0.46)              | ~47 (0.76)               | 8.8 over 53 months Ranibuzimab/bevacuzimab                  | -                   |
| Kang, 42<sup>14</sup>   | Non-caucasian           | ~45 (0.78)                   | ~53<sup>§</sup>          | ~53<sup>§</sup>           | 6.42 over 5 years Ranibuzimab/bevacuzimab                   | All had initial PDT |
| Hikichi, 66<sup>13</sup> | Non-caucasian           | ~67 (0.34)                   | ~75<sup>§</sup>          | ~70 (0.32)               | 21.5 over 6 years Ranibuzimab                                | -                   |

~ Converted from logMar decimal to logMar letters

† Combination anti-VEGF and PDT therapy group

‡ Anti-VEGF monotherapy group

§ Inferred from plotted points on graph

¶ Early Treatment Diabetic Retinopathy Study (ETDRS) letters

The total median number of six injections in the first year in our cohort lies upon the upper range of studies which enrolled Non-Caucasians, but is consistent with Singaporean and Australian studies [Table 4]. Gillies et. al. has demonstrated a strong
relationship between the number of anti-VEGF intravitreal injections and final visual outcome in long term observation studies for neovascular age-related macular degeneration (nAMD). In the multivariate analysis by Fenner et al, poor baseline vision and higher number of injections were also strongly predictive of visual improvement.

Head-to-head comparison with landmark trials, such as EVEREST and PLANET, is confounded by differences in baseline characteristics, choice of anti-VEGF agent, dosing intervals and timing of PDT. Whilst PLANET found Aflibercept monotherapy was non-inferior to Aflibercept combined with PDT rescue, EVEREST II demonstrated superior visual gains with combination therapy compared with Ranibuzimab monotherapy. In spite of these differences, a higher proportion of patients in the monotherapy arm of PLANET achieved disease inactivity after three injections compared to EVEREST, suggesting that Aflibercept may be more effective in treating individuals with PCV than Ranibuzimab. It is also inferable from other major trials on diabetic macular oedema and retinal vein occlusions, that Bevacuzimab may be inferior to Ranibuzimab and Aflibercept in the treatment of PCV. Hence, the conclusion from PLANET that anti-VEGF monotherapy is non-inferior to anti-VEGF with PDT rescue may not generalisable towards Bevacuzimab. Despite this, Bevacuzimab remains the first-line agent to treat nAMD and PCV in many health economies due to its cost-effectiveness. This study provides reassurance that Bevacuzimab monotherapy with rescue PDT or Aflibercept reserved for non-responders, yielded good visual outcomes in the long-term.

Consistent with other published data, we found that both the demographics and the morphological characteristics of PCV differed according to ethnicity. It is well described that the prevalence of PCV among those diagnosed with nAMD is higher in Asians (20-60%) compared to Caucasians (4-10%). PCV also tends to present a decade later in Caucasians compared to Asians and whilst there is a male predominance in Asians, the opposite is seen in Caucasians. In addition to the demographic differences, there also appears to be distinct anatomical differences between ethnic groups. Whilst Asians tend to present with large lesions and BVNs that have a predilection to involve the central macula, Caucasians tend to present with smaller lesions which often spare the fovea. Our findings mirror those previously reported; Caucasians tended to be older, presenting with solitary macular polyps or clusters which filled in the venous phase, with no accompanying BVN, while Asians were more likely to have strings or clusters in the central macula area with large associated BVNs. In the current study, Caucasian patients tend to manifest a different disease phenotype, presented with better visual acuity and reported superior long-term visual outcomes compared to Non-Caucasian patients. These findings then raise the possibility that the observed differences in clinical presentation of PCV may influence how the two ethnic groups respond to treatment. If so, whilst Bevacuzimab is favoured for its cost-effectiveness and appears to deliver acceptable results to Caucasians with PCV, our results suggest that PDT or alternative anti-VEGF agents should be considered earlier in Non-Caucasian eyes with PCV.

This study has limitations inherent to observational studies that should be acknowledged. The recruitment of patients using ICG logs and a separate analysis of excluded patients were purposefully done to mitigate selection bias. Unlike randomised controlled trials, case and treatment selection were performed without reference to an adjudication centre or study protocols. The data presented therefore has a lower internal validity but is still meaningful because they are an accurate representation of decisions made in real-world practice. ICG is not routinely performed on all individuals who present with nAMD and is instead only performed if PCV is suspected. This practice is likely to have led to the unjustified exclusion of some patients with PCV being managed in our unit. It could have also resulted in an underestimation of ICG biomarkers such as branching vascular networks and polyp clusters. Our study included patients that were diagnosed using non-ICG criteria, which has a specificity of 0.86 – 0.91. Although these figures allow for a small proportion of false positive cases, it is another reflection of real-world practice where access to ICG is limited.

In conclusion, Caucasian patients have a preponderance to present with solitary, peripapillary polypoid lesions and have good visual outcomes up to three years with predominately Bevacuzimab anti-VEGF monotherapy. Conversely, Non-Caucasian patients, who are more likely to present with PCV at a younger age with poor visual acuity and foveal involvement, had poorer visual outcomes and may have benefited from early PDT or switching to an alternative anti-VEGF agent.

**Abbreviations**

Anti-VEGF: anti vascular endothelial growth factor
Declarations

Ethics approval and consent to participate

The study protocols was approved by the Auckland District Health Board Research Review committee, approval number A+9628. This study was conducted in accordance with the tenets of the Declaration of Helsinki. The Auckland District Health Board Research Review committee waived the requirements for informed consent because of the retrospective nature of the study and use of anonymized retinal images and clinical data. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable

Availability of data and materials

The datasets generated and analysed during the current study are not publicly available due to potential compromise to individual privacy but are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

There are no sources of funding to declare.
Authors' contributions

AY and NW performed data collection, interpretation, and analysis. AY and DS wrote the main manuscript text. All authors read and approved the final manuscript.

Acknowledgements

We would like to acknowledge the University of Auckland and Auckland District Health Board for their facilities that supported this research project.

References

1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina (Philadelphia, Pa). 2012;32:1-8.

2. Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of 'expanded spectra' - a review. Clinical & experimental ophthalmology. 2018;46(2):189-200.

3. Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen SJ, Kim JE, et al. Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2021;128(3):443-52.

4. Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2017;135(11):1206-13.

5. Lee WK, Iida T, Ogura Y, Chen S-J, Wong TY, Mitchell P, et al. Efficacy and Safety of Intravitreal Aibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmology. 2018;136(7):786-93.

6. Corvi F, Chandra S, Invernizzi A, Pace L, Viola F, Sivaprasad S, et al. Multimodal Imaging Comparison of Polypoidal Choroidal Vasculopathy Between Asian and Caucasian Populations. American journal of ophthalmology. 2022;234:108-16.

7. Stats NZ. Auckland Region Census Place Summaries. 2018.

8. Gillies MC, Walton R, Liong J, Arnold JJ, McAllister I, Morlet N, et al. Ecient capture of high-quality data on outcomes of treatment for macular diseases: the ght retinal blindness! Project. Retina (Philadelphia, Pa). 2014;34(1):188-95.

9. Stats NZ. Ethnicity New Zealand Standard Classication. 2005.

10. Chang YS, Kim JH, Kim KM, Kim JW, Lee TG, Kim CG, et al. Long-term outcomes of anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Journal of Ocular Pharmacology and Therapeutics. 2016;32(4):219-24.

11. Gharehbagh SS, Subhi Y, Sørensen TL. Efficacy of aflibercept for polypoidal choroidal vasculopathy in Caucasians. Acta Ophthalmol. 2018;96(1):e94-e5.

12. Hikichi T. Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2018;102(1):97-101.

13. Kang HM, Kim YM, Koh HJ. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. American journal of ophthalmology. 2013;155(3):438-47. e1.

14. Wataru K, Sugiyama A, Yoneyama S, Matsubara M, Fukuda Y, Parikh R, et al. Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. PLOS ONE.
15. Fenner BJ, Ting DSW, Tan ACS, Teo K, Chan CM, Mathur R, et al. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians. Ophthalmol Retina. 2020;4(4):403-14.

16. Koh AH, Chen L-J, Chen S-J, Chen Y, Giridhar A, Iida T, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina (Philadelphia, Pa). 2013;33(4):686-716.

17. Teo KYC, Jordan-Yu JM, Tan AC, Yeo IY, Mathur R, Chan CM, et al. Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy. British Journal of Ophthalmology. 2021.

18. Gillies M, Arnold J, Bhandari S, Essex RW, Young S, Squirrel D, et al. Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. Am J Ophthalmol. 2020;210:116-24.

19. Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology. 2015;122(9):1837-45.

20. Hykin P, Prevost AT, Sivaprasad S, Vasconcelos JC, Murphy C, Kelly J, et al. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technol Assess. 2021;25(38):1-196.

21. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123(6):1351-9.

22. Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, et al. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol. 2016;165:1-6.

23. Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina (Philadelphia, Pa). 2014;34(11):2192-201.

24. Byeon SH, Lee SC, Oh H-S, Kim SS, Koh HJ, Kwon OW. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Japanese journal of ophthalmology. 2008;52(1):57-62.

25. Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Archives of ophthalmology (Chicago, Ill : 1960). 2003;121(10):1392-6.

26. Wong CW, Yanagi Y, Lee W-K, Ogura Y, Yeo I, Wong TY, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Progress in retinal and eye research. 2016;53:107-39.

27. Ladas ID, Rouvas AA, Moschos MM, Synodinos EE, Karagiannis DA, Koutsandrea CN. Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population. Eye (Lond). 2004;18(5):455-9.

28. Lafaut B, Leys A, Snyers B, Rasquin F, De Laey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefes archive for clinical and experimental ophthalmology. 2000;238(9):752-9.

29. Scassellati-Sforzolini B, Mariotti C, Bryan R, Yannuzzi LA, Giuliani M, Giovannini A. Polypoidal choroidal vasculopathy in Italy. Retina (Philadelphia, Pa). 2001;21(2):121-5.

30. Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Archives of ophthalmology. 1999;117(11):1503-10.

31. van Dijk EHC, Mohabati D, Veselinovic S, Chung WH, Dijkman G, Boon CJF. The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification. Graefes Arch Clin Exp Ophthalmol.
32. Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55(6):501-15.

33. Kwok AK, Lai TY, Chan CW, Neoh EL, Lam DS. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol. 2002;86(8):892-7.

34. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144(1):15-22.

35. Uyama M, Matsubara T, Fukushima I, Matsunaga H, Iwashita K, Nagai Y, et al. Idiopathic Polypoidal Choroidal Vasculopathy in Japanese Patients. Archives of Ophthalmology. 1999;117(8):1035-42.

36. Wen F, Chen C, Wu D, Li H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2004;242(8):625-9.

37. Coscas G, Lupidi M, Coscas F, Benjelloun F, Zerbib J, Dirani A, et al. Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration. Investigative Ophthalmology & Visual Science. 2015;56(5):3187-95.

38. Hatz K, Prünte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. British Journal of Ophthalmology. 2014;98(2):188-94.

39. Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, et al. Polypoidal choroidal vasculopathy: natural history. American journal of ophthalmology. 2002;133(5):639-48.

40. Ahuja RM, Stanga PE, Vingerling JR, Reck AC, Bird AC. Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments. British journal of ophthalmology. 2000;84(5):479-84.

**Figures**
Figure 1
Flowchart Outlining the Patient Selection Process and Reasons for Patient Exclusion and Lost to Follow Up.

FRB! : Fight Retinal Blindness, RPE: Retinal Pigment Epithelium, PCV: Polypoidal choroidal vasculopathy, CNVM: Choroidal neovascular membrane, ICG: Indocyanine green angiography, OCT: Optical coherence tomography.

† last observation carried forward for three patients that were discharged due to poor visual prognosis
‡ per Non-ICG Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup
§ as per ICG diagnostic criteria in EVEREST
Figure 2

A: Mean ± standard deviation, best corrected visual acuity in LogMar Letters over the 3 years of follow up. B: LOESS regression curve of mean visual acuity (VA) ± 95% confidence interval, stratified according to ethnicity. C: LOESS regression curve of mean visual acuity (VA) ± 95% confidence interval, stratified according to baseline VA, the dotted lines represent the cut-off values of 70 and 35 letters.

Figure 3

Kaplan Meier Survival Curve showing the proportion of patients achieving lesion inactivity.